SELECT
2023
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
In 17,604 patients with obesity and cardiovascular disease but without diabetes, semaglutide reduced major adverse cardiovascular events compared with placebo.
Result
Efficacy: CV death, MI or strokeHR 0.8
Below 1 favours semaglutide, above 1 favours placebo.
- Absolute difference
- 1.5 points
The absolute difference is derived from the event rates.
Also reported: Mean weight loss 9.4 %.
- Subtopic
- GLP-1 RA
- Design
- Double-blind RCT
- Relevance
- Practice-defining: a trial the guidelines cite as evidence.
- Source
- Lincoff AM, et al. N Engl J Med. 2023;389(24):2221-2232.doi 10.1056/NEJMoa2307563
Discussion & critique
First trial to show cardiovascular risk reduction from treating obesity itself, without diabetes. How much of the benefit is weight loss versus direct drug effect is unresolved.